Gilead Sciences: O'Day proposes $18.8M share sale
The prior three-month record includes 10b5-1 sales dated September 1 through November 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
A proposed sale for Director and Officer Daniel O'Day involves 112,429 shares of Gilead Sciences, Inc. common stock, with a stated aggregate market value of $18,828,484.63 and an approximate sale date of November 4, 2026. Morgan Stanley Smith Barney LLC is named as broker. The shares are to be received through stock-option exercises over the next three months, and acquisition and payment dates are tied to exercise/sale dates.
Key Figures
Key Terms
Rule 144 regulatory
10b5-1 Sales regulatory
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior GILD sales did Daniel O'Day report?
AI-generated analysis. How Rhea-AI works. Not financial advice.